Watch for IND filing and Phase 1 initiation timeline from Caspian; the comparative data vs BMF-219 is a key differentiator. No clinical validation yet — next catalyst is regulatory clearance to begin human trials.
Price Chart
Executive Summary
Kura Oncology and Caspian Therapeutics announced preclinical data for KO-7246, a menin inhibitor for diabetes, showing β-cell regeneration and durable glycemic control in Type 1 and Type 2 diabetes models. The data position KO-7246 as a potential best-in-class candidate, but remain preclinical with no clinical data or regulatory milestones yet.
Key Facts
- KO-7246 regenerated functional β-cell mass and normalized fasting blood glucose in a rat model of Type 1 diabetes, with pancreatic islets regenerated to 40-90% of healthy controls by Day 56.
- In a mouse model of Type 2 diabetes, KO-7246 produced a 3.4-fold increase in β-cell mass and demonstrated enhanced activity in combination with semaglutide.
- KO-7246 showed potent menin inhibition in biochemical and cellular assays, while comparator BMF-219 (icovamenib) showed no discernable menin activity and instead inhibited CDK9.
- KO-7246 is in IND-enabling development; Caspian plans to evaluate it in a Phase 1 program for diabetes.
- Data were generated by Kura Oncology prior to the launch of Caspian Therapeutics in September 2026.
Financial Impact
No financial figures provided; preclinical data only — no revenue, costs, or deal terms disclosed.
Risk Factors
- Preclinical results may not translate to human efficacy or safety.
- KO-7246 is early-stage (IND-enabling); clinical development timeline and regulatory path are uncertain.
- Competition from other menin inhibitors and GLP-1 therapies; BMF-219 (icovamenib) is already in clinical development for diabetes.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370530 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | Insider Cluster | $10.71 | awaiting T+60 | — | $9.90 (+7.56%) |
Sep 29, 2026 28d ago | Press Release | $10.81 | awaiting T+60 | — | $9.90 (−8.38%) |
Sep 9, 2026 6w ago | 8-K | $12.09 | awaiting T+60 | — | $9.90 (−18.11%) |
Sep 8, 2026 7w ago | 8-K | $12.52 | awaiting T+60 | — | $9.90 (−20.93%) |
Aug 24, 2026 9w ago | Insider Cluster | $13.59 | awaiting T+60 | — | $9.90 (−27.15%) |
Aug 21, 2026 9w ago | Insider Cluster | $12.40 | awaiting T+60 | — | $9.90 (−20.16%) |
Aug 17, 2026 10w ago | Insider Buy | $12.33 | awaiting T+60 | — | $9.90 (−19.71%) |
Aug 12, 2026 10w ago | Press Release | $10.09 | awaiting T+60 | — | $9.90 (−1.88%) |
Aug 5, 2026 11w ago | Press Release | $9.20 | awaiting T+60 | — | $9.90 (+7.61%) |
Jul 29, 2026 12w ago | 8-K | $9.31 $9.61 | ▲ +3.22% | ▲ +0.76% | $9.90 (+6.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers